View ValuationPrecision Biosensor 将来の成長Future 基準チェック /06現在、 Precision Biosensorの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長45.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 07Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South KoreaNew Risk • Nov 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.4b market cap, or US$35.6m).New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩32.7b market cap, or US$22.6m).お知らせ • Nov 03Precision Biosensor, Inc. announced that it has received KRW 17.00000112 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.On November 3, 2025, Precision Biosensor, Inc announced that it has raised KRW 17,000,001,120 in funding and closed the transaction.分析記事 • Jun 19Does Precision Biosensor (KOSDAQ:335810) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩1.8b free cash flow). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩40.8b market cap, or US$29.6m).Reported Earnings • Mar 25Full year 2024 earnings released: ₩629 loss per share (vs ₩387 loss in FY 2023)Full year 2024 results: ₩629 loss per share (further deteriorated from ₩387 loss in FY 2023). Revenue: ₩19.1b (down 6.2% from FY 2023). Net loss: ₩7.31b (loss widened 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 06Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea分析記事 • Dec 16Precision Biosensor, Inc.'s (KOSDAQ:335810) Business Is Yet to Catch Up With Its Share PriceWith a median price-to-sales (or "P/S") ratio of close to 2.2x in the Medical Equipment industry in Korea, you could be...分析記事 • Sep 10Some Confidence Is Lacking In Precision Biosensor, Inc. (KOSDAQ:335810) As Shares Slide 30%Precision Biosensor, Inc. ( KOSDAQ:335810 ) shareholders that were waiting for something to happen have been dealt a...分析記事 • Aug 26We Think Precision Biosensor (KOSDAQ:335810) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jul 02Subdued Growth No Barrier To Precision Biosensor, Inc.'s (KOSDAQ:335810) PriceWhen close to half the companies in the Medical Equipment industry in Korea have price-to-sales ratios (or "P/S") below...New Risk • May 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩7.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.6b free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩49.4b market cap, or US$36.2m).Reported Earnings • Mar 22Full year 2023 earnings released: ₩387 loss per share (vs ₩590 loss in FY 2022)Full year 2023 results: ₩387 loss per share (improved from ₩590 loss in FY 2022). Revenue: ₩20.4b (flat on FY 2022). Net loss: ₩4.49b (loss narrowed 34% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 07Precision Biosensor, Inc. announced that it expects to receive KRW 3 billion in funding from Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd. and another investorPrecision Biosensor, Inc. announced a private placement to issue Series 3 Bearer Interest Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 3,000,000,000 on February 6, 2024. The transaction will include participation from new investors Shinhan Investment & Securities Co., Ltd. for KRW 1,000,000,000, Korea Investment & Securities Co., Ltd. (In the fiduciary position of Fund 1) for KRW 500,000,000 and JB Mezzanine New Technology Business Investment No. 2 for KRW 1,500,000,000. The bonds bear zero coupon rate and 3% maturity rate and matures on February 9, 2029. The transaction has been approved by the shareholders of the company and is expected to close on February 8, 2024. The bonds are 100% convertible into 596,658 shares at a fixed conversion price of KRW 5,028 from February 8, 2025 to January 8, 2029.Reported Earnings • Mar 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ₩368 loss per share (up from ₩550 loss in FY 2020). Revenue: ₩15.9b (up 83% from FY 2020). Net loss: ₩4.15b (loss narrowed 16% from FY 2020). Revenue was in line with analyst estimates.Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩58.00 loss per share (vs ₩36.63 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩4.67b (down 8.1% from 3Q 2020). Net loss: ₩655.8m (down 280% from profit in 3Q 2020). このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Precision Biosensor は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A335810 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202622,336-7,874-1,000-812N/A12/31/202519,926-10,023-1,670-1,513N/A9/30/202519,737-7,876-1,615-1,536N/A6/30/202519,361-8,905-2,069-2,005N/A3/31/202519,588-7,643-1,791-1,736N/A12/31/202419,134-7,305-1,509-1,444N/A9/30/202418,215-8,009-2,107-1,656N/A6/30/202417,135-6,806-6,833-2,700N/A3/31/202418,103-5,838-7,561-2,157N/A12/31/202320,391-4,490-9,006-1,953N/A9/30/202320,570-4,231-10,966910N/A6/30/202320,885-5,056-10,0301,216N/A3/31/202319,787-7,016-13,960-1,457N/A12/31/202220,458-6,806-17,503-2,576N/A9/30/202222,808-6,251-15,860-5,001N/A6/30/202223,500-4,733-15,108-5,940N/A3/31/202221,233-3,308-14,024-3,696N/A12/31/202115,887-4,152-13,752-4,575N/A9/30/202114,255-2,250-13,952-4,032N/A6/30/202111,111-2,215-12,200-3,547N/A3/31/20219,447-4,947-11,193-6,188N/A12/31/20208,685-4,953-6,950-4,840N/A9/30/20205,292-6,221-5,241-4,898N/A12/31/20196,205-405N/A-2,128N/A12/31/20184,588-4,040N/A-2,848N/A12/31/20174,406-2,455N/A-2,783N/A12/31/20164,913-1,294N/A-2,095N/A12/31/20151,387-1,425N/A-923N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A335810の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A335810の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A335810の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A335810の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A335810の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A335810の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 13:31終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Precision Biosensor, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 07Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea
New Risk • Nov 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.4b market cap, or US$35.6m).
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩32.7b market cap, or US$22.6m).
お知らせ • Nov 03Precision Biosensor, Inc. announced that it has received KRW 17.00000112 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.On November 3, 2025, Precision Biosensor, Inc announced that it has raised KRW 17,000,001,120 in funding and closed the transaction.
分析記事 • Jun 19Does Precision Biosensor (KOSDAQ:335810) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩1.8b free cash flow). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩40.8b market cap, or US$29.6m).
Reported Earnings • Mar 25Full year 2024 earnings released: ₩629 loss per share (vs ₩387 loss in FY 2023)Full year 2024 results: ₩629 loss per share (further deteriorated from ₩387 loss in FY 2023). Revenue: ₩19.1b (down 6.2% from FY 2023). Net loss: ₩7.31b (loss widened 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 06Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea
分析記事 • Dec 16Precision Biosensor, Inc.'s (KOSDAQ:335810) Business Is Yet to Catch Up With Its Share PriceWith a median price-to-sales (or "P/S") ratio of close to 2.2x in the Medical Equipment industry in Korea, you could be...
分析記事 • Sep 10Some Confidence Is Lacking In Precision Biosensor, Inc. (KOSDAQ:335810) As Shares Slide 30%Precision Biosensor, Inc. ( KOSDAQ:335810 ) shareholders that were waiting for something to happen have been dealt a...
分析記事 • Aug 26We Think Precision Biosensor (KOSDAQ:335810) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Jul 02Subdued Growth No Barrier To Precision Biosensor, Inc.'s (KOSDAQ:335810) PriceWhen close to half the companies in the Medical Equipment industry in Korea have price-to-sales ratios (or "P/S") below...
New Risk • May 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩7.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.6b free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩49.4b market cap, or US$36.2m).
Reported Earnings • Mar 22Full year 2023 earnings released: ₩387 loss per share (vs ₩590 loss in FY 2022)Full year 2023 results: ₩387 loss per share (improved from ₩590 loss in FY 2022). Revenue: ₩20.4b (flat on FY 2022). Net loss: ₩4.49b (loss narrowed 34% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 07Precision Biosensor, Inc. announced that it expects to receive KRW 3 billion in funding from Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd. and another investorPrecision Biosensor, Inc. announced a private placement to issue Series 3 Bearer Interest Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 3,000,000,000 on February 6, 2024. The transaction will include participation from new investors Shinhan Investment & Securities Co., Ltd. for KRW 1,000,000,000, Korea Investment & Securities Co., Ltd. (In the fiduciary position of Fund 1) for KRW 500,000,000 and JB Mezzanine New Technology Business Investment No. 2 for KRW 1,500,000,000. The bonds bear zero coupon rate and 3% maturity rate and matures on February 9, 2029. The transaction has been approved by the shareholders of the company and is expected to close on February 8, 2024. The bonds are 100% convertible into 596,658 shares at a fixed conversion price of KRW 5,028 from February 8, 2025 to January 8, 2029.
Reported Earnings • Mar 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ₩368 loss per share (up from ₩550 loss in FY 2020). Revenue: ₩15.9b (up 83% from FY 2020). Net loss: ₩4.15b (loss narrowed 16% from FY 2020). Revenue was in line with analyst estimates.
Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩58.00 loss per share (vs ₩36.63 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩4.67b (down 8.1% from 3Q 2020). Net loss: ₩655.8m (down 280% from profit in 3Q 2020).